Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WINDLAS BIOTECH Gains 7%; BSE HEALTHCARE Index Down 0.5%
Wed, 14 Aug 14:20

WINDLAS BIOTECH Gains 7%; BSE HEALTHCARE Index Down 0.5%Image source: Eoneren/www.istockphoto.com

WINDLAS BIOTECH share price has zoomed 7% and is presently trading at Rs 829.7.

Meanwhile, the BSE HEALTHCARE index is at 40,806.1 (down 0.5%).

Among the top gainers in the BSE HEALTHCARE index today are APOLLO HOSPITALS (up 1.7%) and J.B.Chemicals (up 1.5%).

Divis Laboratories (down 4.1%) and IPCA Labs (down 3.7%) are among the top losers today.

Over the last one year, WINDLAS BIOTECH has moved up from Rs 384.0 to Rs 829.7, registering a gain of Rs 445.7 (up 116.1%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,819.2 to 40,806.1, registering a gain of 46.7% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 129.4%), GSK Pharma (up 99.8%) and Jubilant Pharmova (up 98.1%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 79,156.5 (up 0.3%).

The top gainers among the BSE Sensex today are TCS (up 2.0%) and HCl Tech. (up 1.8%). The most traded stocks in the BSE Sensex are Tata Steel and Infosys.

In the meantime, NSE Nifty is at 24,172.5 (up 0.1%). TCS and HCl Tech. are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,401.9 to 79,156.5, registering a gain of 13,754.6 points (up 21.0%).

WINDLAS BIOTECH Financial Update...

WINDLAS BIOTECH net profit grew 48.5% YoY to Rs 170 million for the quarter ended March 2024, compared to a profit of Rs 114 million a year ago. Net sales rose 21.7% to Rs 1,713 million during the period as against Rs 1,407 million in January-March 2023.

For the year ended March 2023, WINDLAS BIOTECH reported 11.9% increase in net profit to Rs 426 million compared to net profit of Rs 381 million during FY22. Revenue of the company grew 10.1% to Rs 5,131 million during FY23.

The current Price to earnings ratio of WINDLAS BIOTECH, based on rolling 12 month earnings, stands at 29.8.


Equitymaster requests your view! Post a comment on "WINDLAS BIOTECH Gains 7%; BSE HEALTHCARE Index Down 0.5%". Click here!